Abstract
Strong lines of evidence have established a critical role for the homeodomain protein HOXB7 in cancer. Specifically, molecular and cellular studies have demonstrated that HOXB7 is a master regulatory gene, capable of orchestrating a variety of target molecules, resulting in the activation of several oncogenic pathways. HOXB7 overexpression correlates with clinical progression and poor outcome of cancer patients. Specific inhibition of HOXB7 is particularly relevant in cancers still lacking effective therapies, such as tamoxifen-resistant breast cancer and melanoma. Mechanistic studies are providing additional targets of therapy, and biomarker studies are further establishing its importance in early diagnosis and prognosis.
Original language | English (US) |
---|---|
Pages (from-to) | 2857-2862 |
Number of pages | 6 |
Journal | Cancer Research |
Volume | 76 |
Issue number | 10 |
DOIs | |
State | Published - May 15 2016 |
ASJC Scopus subject areas
- Oncology
- Cancer Research